Related Experiment Video
Updated: Feb 28, 2026
10:17
The Tail Suspension Test
Published on: January 28, 2012
83.7K
SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium-Treated Patients With Mood Disorders: A
Mete Ercis1, Idil Tarikogullari1, Vanessa K Pazdernik2
1Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Bipolar Disorders
|February 27, 2026
Summary
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improved kidney function in patients with mood disorders on lithium. This suggests SGLT2i may help prevent lithium-associated kidney damage.
Area of Science:
- Nephrology
- Psychiatry
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) show renal benefits in diabetic and non-diabetic patients.
- The impact of SGLT2i on lithium-associated kidney dysfunction is not well understood.
Purpose of the Study:
- To investigate the effect of SGLT2i on estimated glomerular filtration rate (eGFR) trajectories in patients with mood disorders receiving long-term lithium therapy.
Main Methods:
- Historical cohort study of 56 patients with mood disorders on lithium and later SGLT2i.
- Analysis of eGFR changes before and after SGLT2i initiation using linear mixed-effects models.
Main Results:
- Before SGLT2i, eGFR declined by -1.43 mL/min/1.73 m² per year.
- After SGLT2i initiation, eGFR increased by 0.69 mL/min/1.73 m² per year (p=0.025).
Conclusions:
- SGLT2i treatment was linked to improved eGFR trajectories in patients on long-term lithium.
- SGLT2i may mitigate lithium-induced kidney dysfunction, warranting further investigation via randomized controlled trials.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
288
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
288
01:24Mania and Antimanic Drugs: Overview
708
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
708
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
2.0K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316